Emerging Biomarkers in Stage III Melanoma May Improve Patient Management
Source: Cancer Therapy Advisor, May 2021
Increased effort is needed in the development of reliable predictive biomarkers for stage III melanoma, according to a review published in the International Journal of Molecular Sciences.1
Gene expression analysis and the identification of a single gene or a signature correlated with patients’ outcomes could lead to improved patient stratification.